17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period

Grzegorz Stachowiak; Tomasz Pertyński

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2010
vol. 9

Send email

Copy url:

abstract:

Review paper

17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period

Grzegorz Stachowiak

,

Tomasz Pertyński

Przegląd Menopauzalny 2010; 1: 1–4

Online publish date: 2010/02/25

View full text Get citation

Low-dose oral MHT combining 1 mg oestradiol (E2) and 2 mg drospirenone (DRSP) is effective in alleviating climacteric and urogenital symptoms, prevents endometrial hyperplasia, reduces the risk of osteoporosis, and has a positive influence on lipid profile, carbohydrate metabolism, arterial pressure and female quality of life. This safe type of MHT can be a drug of first choice for the big group of women after menopause.

keywords:

17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period

Grzegorz Stachowiak , Tomasz Pertyński

menopause, drospirenone, oestradiol, oral hormonal therapy, progestogens

Grzegorz Stachowiak

,

Tomasz Pertyński